ReviewClinical microbiology reviews1999
Aspergillus fumigatus and aspergillosis.
Review in Clinical microbiology reviews, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 837 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
837 citing papers in PubMed, 2 syntheses or guidelines pooled it, 2,283 citations in OpenAlex.
- Mycotic infection as a risk factor for COVID-19: A meta-analysis.Frontiers in public health · 2022Pooled it
- Pooled it
- Development Framework of Desirability of Outcome Ranking Endpoints for Use in Clinical Trials of Invasive Fungal Diseases.Open forum infectious diseases · 2026Trial
- Unveiling the Bioactive Potential of Shilajit: Integrated Chemical Profiling and Antimicrobial Evaluation via Chromatographic, Spectroscopic, and In Silico Approaches.Chemistry & biodiversity · 2026Article
- MethylSense: high accuracy machine learning-based diagnostics forJournal of clinical microbiology · 2026Article
- Lung Microbiome Diversity, Infection Dynamics, and Microbe-Mediated Cross-Protection.MicrobiologyOpen · 2026Review
- Thermal adaptation crosstalk with azole response through lncRNA inbioRxiv : the preprint server for biology · 2026Article
- A Role for Non-Canonical Caspases in Fungal Allergic Airway Disease.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2026Article
- Systematic Review of Mammalian Models for Experimental Sporotrichosis: Pathogenesis, Methodological Variables, and Ethical Considerations.Animals : an open access journal from MDPI · 2026Review
- α-1,3-Glucan-Driven Remodeling of the Conidial Cell Wall in anJournal of the American Chemical Society · 2026Article
- Antimicrobial effects and mechanism of action of carboxymethyl chitosan-loaded silver ion complexes against drug-resistant Aspergillus fumigatus.Journal of microbiology (Seoul, Korea) · 2026Article
- Imaging of pediatric pulmonary infections: A pictorial review.World journal of clinical pediatrics · 2026Review
- Prevalence and Factors Associated WithOpen forum infectious diseases · 2026Article
- Global epidemiology of azole resistance inJAC-antimicrobial resistance · 2026Review
- Early Antifungal Treatment in Immunocompromised Patients, Including Hematological and Critically Ill Patients.Journal of fungi (Basel, Switzerland) · 2026Review
- Oxidoreductase geneMicrobiology spectrum · 2026Article
- Mycobacterial lipoarabinomannan negatively interferes with macrophage responses to Aspergillus fumigatus in-vitro.PloS one · 2026Article
- Article
- Molecular mechanisms drivingFrontiers in molecular biosciences · 2026Review
- Article
777 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aspergillus fumigatus is one of the most ubiquitous of the airborne saprophytic fungi. Humans and animals constantly inhale numerous conidia of this fungus. The conidia are normally eliminated in the immunocompetent host by innate immune mechanisms, and aspergilloma and allergic bronchopulmonary aspergillosis, uncommon clinical syndromes, are the only infections observed in such hosts. Thus, A. fumigatus was considered for years to be a weak pathogen. With increases in the number of immunosuppressed patients, however, there has been a dramatic increase in severe and usually fatal invasive aspergillosis, now the most common mold infection worldwide. In this review, the focus is on the biology of A. fumigatus and the diseases it causes. Included are discussions of (i) genomic and molecular characterization of the organism, (ii) clinical and laboratory methods available for the diagnosis of aspergillosis in immunocompetent and immunocompromised hosts, (iii) identification of host and fungal factors that play a role in the establishment of the fungus in vivo, and (iv) problems associated with antifungal therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.